Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD6621
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AZD6621 is an experimental, next-generation tri-specific T-cell engager (TCE) developed by AstraZeneca for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is designed to target six-transmembrane epithelial antigen of prostate-2 (STEAP2) on prostate cancer cells, while simultaneously engaging CD3 and CD8 on T cells. By incorporating a CD8-guided, affinity-optimized CD3 engagement mechanism, AZD6621 preferentially activates CD8+ cytotoxic killer T cells over CD4+ helper T cells. This selective activation is intended to maximize tumor cell destruction while minimizing systemic inflammatory cytokine release, thereby improving the therapeutic index compared to conventional T-cell engagers. AZD6621 is currently being evaluated in a Phase I/II clinical trial (ACTIVATED-4-PC) as a monotherapy for patients with metastatic prostate cancer.
02
Targets
STEAP2 (Six-transmembrane epithelial antigen of the prostate 2)CD3 (T-cell surface glycoprotein CD3)CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on AZD6621.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD6621.